✨✨The 2025 Keystone Symposium on Aging and Gerotherapeutics is coming up and early bird registration ends today! Very excited about our speaker lineup. Check it out!
www.keystonesymposia.org/conferences/...
www.keystonesymposia.org/conferences/...
Aging: New Frontiers in Rejuvenation and Gerotherapeutics | Keystone Symposia
Join us at the Keystone Symposia on Aging: New Frontiers in Rejuvenation and Gerotherapeutics, February 2025, in Breckenridge, with field leaders!
www.keystonesymposia.org
December 23, 2024 at 8:47 PM
✨✨The 2025 Keystone Symposium on Aging and Gerotherapeutics is coming up and early bird registration ends today! Very excited about our speaker lineup. Check it out!
www.keystonesymposia.org/conferences/...
www.keystonesymposia.org/conferences/...
Made it to bluesky just in time to remind everyone that today is the deadline to submit a short talk or scholarship abstract for the upcoming Keystone Symposium on Aging. Join us in Breckenridge in Feb. 2025!
www.keystonesymposia.org/conferences/...
www.keystonesymposia.org/conferences/...
Aging: New Frontiers in Rejuvenation and Gerotherapeutics | Keystone Symposia
Join us at the Keystone Symposia on Aging: New Frontiers in Rejuvenation and Gerotherapeutics, February 2025, in Breckenridge, with field leaders!
www.keystonesymposia.org
November 26, 2024 at 9:31 PM
Made it to bluesky just in time to remind everyone that today is the deadline to submit a short talk or scholarship abstract for the upcoming Keystone Symposium on Aging. Join us in Breckenridge in Feb. 2025!
www.keystonesymposia.org/conferences/...
www.keystonesymposia.org/conferences/...
True. I've been there.
We need public health care and it needs to include preventative gerotherapeutics.
We need public health care and it needs to include preventative gerotherapeutics.
April 8, 2025 at 4:16 PM
True. I've been there.
We need public health care and it needs to include preventative gerotherapeutics.
We need public health care and it needs to include preventative gerotherapeutics.
Register for on-demand access to @keystonesymposia.bsky.social #Aging: New Frontiers in #Rejuvenation and #Gerotherapeutics, to explore emerging research in the field: plos.io/3GRJgsI #KSAging25
Aging: New Frontiers in Rejuvenation and Gerotherapeutics | Keystone Symposia
Join us at the Keystone Symposia on Aging: New Frontiers in Rejuvenation and Gerotherapeutics, February 2025, in Breckenridge, with field leaders!
keysym.us
May 2, 2025 at 9:06 PM
Register for on-demand access to @keystonesymposia.bsky.social #Aging: New Frontiers in #Rejuvenation and #Gerotherapeutics, to explore emerging research in the field: plos.io/3GRJgsI #KSAging25
AFAR Scientific Director Steven Austad, PhD, featured in recent Longevity Roundtable Special of The Drive Podcast on the latest advancements in geroscience, including potential of gerotherapeutics like #Metformin, #Rapamycin and #GLP1s
Listen here: https://buff.ly/4hBXL0W
Listen here: https://buff.ly/4hBXL0W
February 5, 2025 at 4:20 PM
AFAR Scientific Director Steven Austad, PhD, featured in recent Longevity Roundtable Special of The Drive Podcast on the latest advancements in geroscience, including potential of gerotherapeutics like #Metformin, #Rapamycin and #GLP1s
Listen here: https://buff.ly/4hBXL0W
Listen here: https://buff.ly/4hBXL0W
"Repurposed for Aging": Which drugs have the strongest evidence as potential gerotherapeutics? Great discussion of metformin, SLGT2i, and GLP-1RA at #GSA24 by this #endocrinology & #geriatrics #geroscience Dream Team of Dr. Sara Espinoza, Dr. Carolina Solis-Herrera, Dr. Sandra Aleksic, and me.
November 14, 2024 at 12:44 AM
"Repurposed for Aging": Which drugs have the strongest evidence as potential gerotherapeutics? Great discussion of metformin, SLGT2i, and GLP-1RA at #GSA24 by this #endocrinology & #geriatrics #geroscience Dream Team of Dr. Sara Espinoza, Dr. Carolina Solis-Herrera, Dr. Sandra Aleksic, and me.
An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted Gerotherapeutics
www.medrxiv.org/content/10.6...
www.medrxiv.org/content/10.6...
www.medrxiv.org
April 20, 2026 at 10:34 PM
An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted Gerotherapeutics
www.medrxiv.org/content/10.6...
www.medrxiv.org/content/10.6...
Now seeking submissions for the December 2025 issue: Aging is Bad for You? journalofethics.ama-assn.or...
December 2025: Aging Is Bad for You?
At some point along life’s trajectory, growing becomes aging, and gerotherapeutics—biologically-based approaches to health that target processes of aging—seems to be poised to respond. This theme issue investigates ethical valences of what this field
journalofethics.ama-assn.org
December 17, 2024 at 9:42 PM
Now seeking submissions for the December 2025 issue: Aging is Bad for You? journalofethics.ama-assn.or...
Aged blood vessel cells contribute to metabolic disorders such as diabetes, and targeting these cells with senolytic compounds like fisetin shows promise for improving metabolic health.
Aged blood vessel cells drive metabolic diseases, preclinical study suggests
Investigators from the Center for Advanced Gerotherapeutics at Cedars-Sinai found that aged blood vessel cells play a key role in the development of metabolic disorders, including diabetes.
medicalxpress.com
November 20, 2025 at 4:00 PM
Aged blood vessel cells contribute to metabolic disorders such as diabetes, and targeting these cells with senolytic compounds like fisetin shows promise for improving metabolic health.
NEXT WEEK - September 22nd from 3-4pm ET: free #webinar exploring the state of Gerotherapeutics to extend healthspan. Featuring experts from @ahlresearch.bsky.social, BioAge Labs, Cedars-Sinai LA, the NIA, and @uthealthsa.bsky.social
Learn more & RSVP here: buff.ly/3tr4wv5
Learn more & RSVP here: buff.ly/3tr4wv5
September 15, 2025 at 3:59 PM
NEXT WEEK - September 22nd from 3-4pm ET: free #webinar exploring the state of Gerotherapeutics to extend healthspan. Featuring experts from @ahlresearch.bsky.social, BioAge Labs, Cedars-Sinai LA, the NIA, and @uthealthsa.bsky.social
Learn more & RSVP here: buff.ly/3tr4wv5
Learn more & RSVP here: buff.ly/3tr4wv5
Semaglutide slows epigenetic aging in HIV-associated lipohypertrophy. In a 32-week trial, 45 on semaglutide vs. 39 on placebo showed promising results. RT if intrigued! PMID:42156721, Nat Commun 2026, @NatureComms https://doi.org/10.1038/s41467-026-72861-3 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy | Nature Communications
Glucagon-like peptide-1 (GLP-1) receptor agonists have attracted interest as gerotherapeutics, yet clinical-trial evidence for their effects on biological aging is lacking. We report a post hoc exploratory epigenetic age analysis of a 32-week, randomized, double-blind, placebo-controlled phase 2b trial (NCT04019197) of semaglutide in adults with human immunodeficiency virus (HIV)-associated lipohypertrophy (semaglutide n = 45; placebo n = 39). The parent trial’s primary endpoint was change in visceral adipose tissue, with secondary cardiometabolic and body-composition endpoints; epigenetic aging was not pre-specified. To address this gap, we profiled peripheral-blood DNA methylation (DNAm) at baseline and week 32 to assess semaglutide versus placebo on first-, second-, and third-generation epigenetic aging measures. In adjusted analyses, semaglutide reduced epigenetic aging across multiple second- and third-generation clocks, including PhenoAge ( − 4.9 years/year, p = 0.004), PCGrimAge
doi.org
June 22, 2026 at 6:00 AM
@erictopol.bsky.social is right — we haven’t rigorously validated gerotherapeutics in humans, and even if we did, we’d need to show they also compress morbidity.
Some source for optimism: for some animal models, better healthspan can track increased longevity.
pmc.ncbi.nlm.nih.gov/articles/PMC...
Some source for optimism: for some animal models, better healthspan can track increased longevity.
pmc.ncbi.nlm.nih.gov/articles/PMC...
pmc.ncbi.nlm.nih.gov
August 28, 2025 at 10:45 PM
@erictopol.bsky.social is right — we haven’t rigorously validated gerotherapeutics in humans, and even if we did, we’d need to show they also compress morbidity.
Some source for optimism: for some animal models, better healthspan can track increased longevity.
pmc.ncbi.nlm.nih.gov/articles/PMC...
Some source for optimism: for some animal models, better healthspan can track increased longevity.
pmc.ncbi.nlm.nih.gov/articles/PMC...
LAST CHANCE to RSVP for today’s free #webinar with @ahlresearch.bsky.social exploring the state of Gerotherapeutics to extend healthspan. Featuring experts from BioAge Labs, Cedars-Sinai LA, the NIA, and @uthealthsa.bsky.social
Learn more & RSVP here: buff.ly/3tr4wv5
Learn more & RSVP here: buff.ly/3tr4wv5
September 22, 2025 at 2:05 PM
LAST CHANCE to RSVP for today’s free #webinar with @ahlresearch.bsky.social exploring the state of Gerotherapeutics to extend healthspan. Featuring experts from BioAge Labs, Cedars-Sinai LA, the NIA, and @uthealthsa.bsky.social
Learn more & RSVP here: buff.ly/3tr4wv5
Learn more & RSVP here: buff.ly/3tr4wv5
Next month, join AFAR & @ahlresearch.bsky.social on 9.22 at 3pm ET for free #webinar on the state of Gerotherapeutics to extend healthspan. Feat. experts from BioAge Labs, Cedars-Sinai, the NIA, & @uthealthsa.bsky.social w/ Dana G. Smith of @nytimes.com. Learn more & RSVP here: buff.ly/3tr4wv5
August 25, 2025 at 6:00 PM
Next month, join AFAR & @ahlresearch.bsky.social on 9.22 at 3pm ET for free #webinar on the state of Gerotherapeutics to extend healthspan. Feat. experts from BioAge Labs, Cedars-Sinai, the NIA, & @uthealthsa.bsky.social w/ Dana G. Smith of @nytimes.com. Learn more & RSVP here: buff.ly/3tr4wv5
🎉 Celebrating 30 years of discovery! The San Antonio Nathan Shock Center at @uthealthsa.bsky.social has been a hub for aging research since 1995—has secured 5 more years of NIA funding! 🧬 Pioneering gerotherapeutics like rapamycin to boost lifespan & healthspan.
🔗 : bit.ly/4mqWn3T
🔗 : bit.ly/4mqWn3T
Thirty years of excellence: San Antonio Nathan Shock Center a global leader in aging research - UT Health San Antonio
Aging affects all living creatures and is the greatest factor in numerous diseases. The greatest health care burdens are borne by diseases in older patients — a population expected to nearly double by...
bit.ly
July 31, 2025 at 10:07 PM
🎉 Celebrating 30 years of discovery! The San Antonio Nathan Shock Center at @uthealthsa.bsky.social has been a hub for aging research since 1995—has secured 5 more years of NIA funding! 🧬 Pioneering gerotherapeutics like rapamycin to boost lifespan & healthspan.
🔗 : bit.ly/4mqWn3T
🔗 : bit.ly/4mqWn3T
A gerotherapeutic would target molecular mechanisms of aging to prevent, delay, or treat multiple chronic diseases and conditions of aging (the geroscience hypothesis). There are no confirmed gerotherapeutics. But are existing clinical data consistent with how a gerotherapeutic would act?
November 14, 2024 at 12:49 AM
A gerotherapeutic would target molecular mechanisms of aging to prevent, delay, or treat multiple chronic diseases and conditions of aging (the geroscience hypothesis). There are no confirmed gerotherapeutics. But are existing clinical data consistent with how a gerotherapeutic would act?
Share your groundbreaking research in a poster presentation and connect with Anne Brunet and other pioneers in the fields of inflammaging and age reversal! Submit your abstracts by 11:59 PM MST on January 27. youtu.be/sz2OXmqzjE0
#KSAging25 #aging #inflammaging #gerotherapeutics #anti-aging
#KSAging25 #aging #inflammaging #gerotherapeutics #anti-aging
Aging Meeting Promo
YouTube video by KeystoneSymposia
youtu.be
January 17, 2025 at 5:48 PM
Share your groundbreaking research in a poster presentation and connect with Anne Brunet and other pioneers in the fields of inflammaging and age reversal! Submit your abstracts by 11:59 PM MST on January 27. youtu.be/sz2OXmqzjE0
#KSAging25 #aging #inflammaging #gerotherapeutics #anti-aging
#KSAging25 #aging #inflammaging #gerotherapeutics #anti-aging
Eski, yaşlı kan damarı hücrelerinin çıkarılması, farelerde diyabetik semptomları hafifletir.
Eskimiş, yaşlanmış kan damarı hücrelerinin çıkarılması, farelerde iltihaplanma ve metabolizma bozukluklarını hafifletti.
Eskimiş, yaşlanmış kan damarı hücrelerinin çıkarılması, farelerde iltihaplanma ve metabolizma bozukluklarını hafifletti.
Aged Blood Vessel Cells Drive Metabolic Diseases
Investigators from the Center for Advanced Gerotherapeutics at Cedars-Sinai found that aged blood vessel cells play a key role in the development of metabolic disorders, including diabetes. The precli...
www.cedars-sinai.org
November 24, 2025 at 10:08 AM
Eski, yaşlı kan damarı hücrelerinin çıkarılması, farelerde diyabetik semptomları hafifletir.
Eskimiş, yaşlanmış kan damarı hücrelerinin çıkarılması, farelerde iltihaplanma ve metabolizma bozukluklarını hafifletti.
Eskimiş, yaşlanmış kan damarı hücrelerinin çıkarılması, farelerde iltihaplanma ve metabolizma bozukluklarını hafifletti.
New special issue of @sciam.bsky.social explores aging research, gerotherapeutics and the longevity dividend of extending healthspan. AFAR Scientific Director Steven N. Austad as well as several other AFAR-affiliated experts and projects are featured.
Read more here: www.afar.org/news/special...
Read more here: www.afar.org/news/special...
Healthspan: The Science of Aging Well
Science has extended the human lifespan, but our later years often bring chronic disease. But it may no longer need to be that way. Through careful reporting and expert commentary, this special…
ow.ly
April 8, 2025 at 4:01 PM
New special issue of @sciam.bsky.social explores aging research, gerotherapeutics and the longevity dividend of extending healthspan. AFAR Scientific Director Steven N. Austad as well as several other AFAR-affiliated experts and projects are featured.
Read more here: www.afar.org/news/special...
Read more here: www.afar.org/news/special...
Navigating the Future: Massive Investments in Longevity Biotech Expected to Transform Healthcare#London#United_Kingdom#Health_Innovation#Longevity_Biotech#gerotherapeutics
Navigating the Future: Massive Investments in Longevity Biotech Expected to Transform Healthcare
Investors are pouring over $30 billion into longevity biotech as the industry anticipates groundbreaking gerotherapeutic drugs by 2035.
third-news.com
September 16, 2026 at 2:48 PM
Navigating the Future: Massive Investments in Longevity Biotech Expected to Transform Healthcare#London#United_Kingdom#Health_Innovation#Longevity_Biotech#gerotherapeutics
It’s about @TIME.com we properly test interventions intended to extend healthspan!
The goal of #XPRIZEHealthspan is to understand how to validate gerotherapeutics and ensure time spent in elderhood is lived with strength, vitality and happiness. Not just more years, but more good years.
The goal of #XPRIZEHealthspan is to understand how to validate gerotherapeutics and ensure time spent in elderhood is lived with strength, vitality and happiness. Not just more years, but more good years.
X Prize Healthspan Is Testing the Best Ideas for Slowing Aging
The seven-year competition just named its top 10 finalists.
time.com
August 24, 2026 at 12:38 PM
It’s about @TIME.com we properly test interventions intended to extend healthspan!
The goal of #XPRIZEHealthspan is to understand how to validate gerotherapeutics and ensure time spent in elderhood is lived with strength, vitality and happiness. Not just more years, but more good years.
The goal of #XPRIZEHealthspan is to understand how to validate gerotherapeutics and ensure time spent in elderhood is lived with strength, vitality and happiness. Not just more years, but more good years.
An accumulating but preliminary body of research has led longevity clinics to market and prescribe GLP-1s as so-called gerotherapeutics—drugs that can target certain biological hallmarks of aging.
Ozempic’s New Frontier: The War on Aging
Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.
www.wsj.com
March 11, 2025 at 2:04 PM
An accumulating but preliminary body of research has led longevity clinics to market and prescribe GLP-1s as so-called gerotherapeutics—drugs that can target certain biological hallmarks of aging.
Reflecting on a standout session from the AHLR 5th Annual Conference, we had the privilege of hearing from Alex Zhavoronkov, Founder and CEO of Insilico Medicine, on the role of AI in developing gerotherapeutics.
Learn more -https://www.linkedin.com/feed/update/urn:li:activity:7302390812229648385
Learn more -https://www.linkedin.com/feed/update/urn:li:activity:7302390812229648385
Academy for Health & Lifespan Research on LinkedIn: Reflecting on a standout session from the AHLR 5th Annual Conference, we…
Reflecting on a standout session from the AHLR 5th Annual Conference, we had the privilege of hearing from Alex Zhavoronkov, Founder and CEO of Insilico…
www.linkedin.com
March 3, 2025 at 6:19 PM
Reflecting on a standout session from the AHLR 5th Annual Conference, we had the privilege of hearing from Alex Zhavoronkov, Founder and CEO of Insilico Medicine, on the role of AI in developing gerotherapeutics.
Learn more -https://www.linkedin.com/feed/update/urn:li:activity:7302390812229648385
Learn more -https://www.linkedin.com/feed/update/urn:li:activity:7302390812229648385
The Academy for Health & Lifespan Research wrapped up its 5th Annual Conference—an event discussing translational strategies, outreach, & the challenges of integrating gerotherapeutics into clinical practice. With thought-provoking panels & inspiring guest speakers, the conference was a success.
February 19, 2025 at 6:17 PM
The Academy for Health & Lifespan Research wrapped up its 5th Annual Conference—an event discussing translational strategies, outreach, & the challenges of integrating gerotherapeutics into clinical practice. With thought-provoking panels & inspiring guest speakers, the conference was a success.